Gene therapy injection for ALS safety study
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a single injection of a gene therapy called INS1202 into the spinal fluid. It is for people with ALS, including those with a specific genetic form (SOD1 mutation). The goal is to see if it is safe and how it affects the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with ALS by a doctor using the Gold Coast criteria.
- Your weight must be in a healthy range (BMI of 18 or higher).
- You must have a functional score (ALSFRS-R) of at least 24 and your ALS symptoms must have started within the last 42 months.
- If you have the SOD1 gene mutation, you may qualify for certain groups. If you have other known familial ALS mutations, you may still be considered.
- You must not have had gene or cell therapy for ALS before, and you cannot be in another treatment study right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether injecting special cells (called Q-Cells) into the spinal cord is safe for people with ALS. It's an early-stage trial, so the main goal is to check safety, but it might help slow down the disease in the future.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial tests whether injecting neural stem cells into the spine can slow down ALS. It is for people with rapidly progressing ALS who have good lung function and a caregiver to help with visits.
This trial tests whether a new medicine, made of tiny capsules containing a protein called nerve growth factor, can help people with ALS. It aims to see if the treatment can slow the disease and improve symptoms.
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.